{"doi":"10.1136/jitc-2024-010960","title":"Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy","abstract":"<jats:p>Immune checkpoint inhibition (ICI) targeting programmed cell death protein-1 (PD1) prevents the elimination of activated cytotoxic T lymphocytes (CTLs) by programmed death-ligand 1/2-expressing cancer and myeloid cells in the tumor microenvironment (TME). ICI has shown its effectiveness in many solid tumors, but it lacks activity against “cold” tumors which lack CTL infiltration, including most of the colon, prostate, lung and breast cancers. Metastatic triple-negative breast cancer (TNBC) responds to PD-1 blockade only in 5–20% cases. Chemotherapy has been shown to have a PD1-sensitizing effect in a fraction of patients with TNBC but the underlying mechanism and the reasoning behind its limitation to only a subset of patients are unknown. Recent data demonstrate the key roles played by paclitaxel-driven Toll-like receptor 4 (TLR4) signaling and the resulting activation of type-1 and type-2 interferon pathways in tumor-associated macrophages, resulting in local M2 to M1 transition and enhanced tumor antigen cross-presentation, in the paclitaxel-driven sensitization of “cold” tumors to ICI. These data and the known ability of the TLR4-activated MyD88-NFκB pathway to mobilize both antitumor and tumor-promoting events in the TME provide new tools to enhance the efficacy of chemo-immunotherapy for metastatic, and potentially early, TNBC and other taxane-sensitive cancers.</jats:p>","journal":"Journal for ImmunoTherapy of Cancer","year":2025,"id":616240,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1026415,"name":"Kathleen M. Kokolus","orcid":"0000-0002-9088-5409","position":1,"is_corresponding":false},{"id":260449,"name":"Shipra Gandhi","orcid":"0000-0003-3506-0284","position":2,"is_corresponding":false},{"id":281558,"name":"Paweł Kaliński","orcid":"0000-0001-7025-3562","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy","abstract":"<jats:p>Immune checkpoint inhibition (ICI) targeting programmed cell death protein-1 (PD1) prevents the elimination of activated cytotoxic T lymphocytes (CTLs) by programmed death-ligand 1/2-expressing cancer and myeloid cells in the tumor microenvironment (TME). ICI has shown its effectiveness in many solid tumors, but it lacks activity against “cold” tumors which lack CTL infiltration, including most of the colon, prostate, lung and breast cancers. Metastatic triple-negative breast cancer (TNBC) responds to PD-1 blockade only in 5–20% cases. Chemotherapy has been shown to have a PD1-sensitizing effect in a fraction of patients with TNBC but the underlying mechanism and the reasoning behind its limitation to only a subset of patients are unknown. Recent data demonstrate the key roles played by paclitaxel-driven Toll-like receptor 4 (TLR4) signaling and the resulting activation of type-1 and type-2 interferon pathways in tumor-associated macrophages, resulting in local M2 to M1 transition and enhanced tumor antigen cross-presentation, in the paclitaxel-driven sensitization of “cold” tumors to ICI. These data and the known ability of the TLR4-activated MyD88-NFκB pathway to mobilize both antitumor and tumor-promoting events in the TME provide new tools to enhance the efficacy of chemo-immunotherapy for metastatic, and potentially early, TNBC and other taxane-sensitive cancers.</jats:p>","is_dataset_classified":null,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40389375","pmcid":"PMC12090863","openalex_id":"https://openalex.org/W4410548694","authors":[],"funders":[{"funder_name":"DOD Peer Reviewed Cancer Research Program","grant_id":"W81XWH-19-1-0674","title":null},{"funder_name":"National Cancer Institute","grant_id":"K08CA279766","title":null},{"funder_name":"National Cancer Institute","grant_id":"P01CA234212","title":null},{"funder_name":"National Cancer Institute","grant_id":"P50CA159981","title":null},{"funder_name":"National Center for Advancing Translational Sciences","grant_id":"KL2TR001413","title":null},{"funder_name":"National Center for Advancing Translational Sciences","grant_id":"R03TR004607","title":null},{"funder_name":"National Center for Advancing Translational Sciences","grant_id":"UL1TR001412","title":null},{"funder_name":"National Institutes of Health","grant_id":"1P50CA159981-01A1","title":"MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1"},{"funder_name":"National Institutes of Health","grant_id":"5KL2TR001413-03","title":"Buffalo Clinical and Translational Research Center"},{"funder_name":"National Institutes of Health","grant_id":"7K08CA279766-02","title":"Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer"},{"funder_name":"National Institutes of Health","grant_id":"3UL1TR001412-08S3","title":"Buffalo Clinical and Translational Research Center"},{"funder_name":"National Institutes of Health","grant_id":"1R03TR004607-01","title":"Identifying the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancer"},{"funder_name":"National Institutes of Health","grant_id":"5P01CA234212-02","title":"Targeting the Chemokine System to Sensitize Tumors to Immunotherapy"},{"funder_name":"Roswell Alliance Foundation","grant_id":"","title":null},{"funder_name":"Jacobs Family Foundation","grant_id":"","title":null}],"total_grants":15,"fwci":4.6506,"citation_percentile":0.95522567,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":9}],"oa_status":"gold","license":"CC BY NC","oa_locations":[{"url":"https://doi.org/10.1136/jitc-2024-010960","host_type":"journal"},{"url":"https://doi.org/10.1136/jitc-2024-010960","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1136/jitc-2024-010960","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40389375","host_type":"repository"},{"url":"https://doaj.org/article/8fba5b13d4d84ccd908fe74cfacb7ce0","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12090863","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12090863","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12090863?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1136/jitc-2024-010960","host_type":""}],"fields_of_study":["Immune cells in cancer","Cancer Immunotherapy and Biomarkers","Immunotherapy and Immune Responses","03 medical and health sciences","0302 clinical medicine","Humans","Paclitaxel","Tumor-Associated Macrophages","Immunotherapy","Interferons","Tumor Microenvironment","Neoplasms","Animals"],"mesh_terms":["Tumor-Associated Macrophages","Animals","Humans","Immunotherapy","Interferons","Neoplasms","Paclitaxel","Tumor Microenvironment"],"keywords":["Immunotherapy","Cancer research","Medicine","Tumor microenvironment","Triple-negative breast cancer","Prostate cancer","Taxane","Cytotoxic T cell","Immune checkpoint","Paclitaxel","Immunology","Immune system","Cancer","Breast cancer","Internal medicine","Biology","Macrophage","Chemotherapy","Immune Checkpoint Inhibitor","Neoplasms","Tumor-Associated Macrophages","Commentary","Neoplasms. Tumors. Oncology. Including cancer and carcinogens","Humans","Animals","Interferons","RC254-282"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T22:22:15.488002Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}